SEO URLwww.firestrike.ai/deals/aerie-pharmaceuticals-alcon-acquisition-2026
acquisitionAnnounced · Feb 5, 2026ophthalmic pharmaceuticalsSource · CredibleArticle · Factual
Alcon acquires Aerie Pharmaceuticals
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$930M
Target
Aerie Pharmaceuticals
NASDAQ: AERI · Durham, North Carolina
Acquirer
Alcon
Full Acquisition
Status
Completed
Alcon agreed to acquire Aerie Pharmaceuticals. Reported deal value: $930M. Status: Completed. Sector: ophthalmic pharmaceuticals. Target headquarters context: Durham, North Carolina, United States.
This page summarizes publicly available information about the transaction as of 2026-02-05. Figures and status may change as filings and press coverage update.
Alcon completed its acquisition of Aerie Pharmaceuticals earlier this month, according to a press release
Deal timeline
Announced
Feb 5, 2026 · optometrytimes.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in ophthalmic pharmaceuticals with a reported deal value of $930M. Figures and status may change as sources update.
Sources: optometrytimes.com · Primary article · FireStrike proprietary index